A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Alcon Research156 enrolled

Overview

The purpose of the study is to evaluate the safety and effectiveness of an investigational therapy for treating patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

156

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

Travoprost 0.004% / Timolol 0.5% Ophthalmic SolutionDRUG

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Timolol VehicleOTHER

Placebo

Latanoprost 0.005% Ophthalmic Solution (XALATAN)DRUG

Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older. * Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension. * Mean IOP in each eye less than 18 mmHg at the screening visit. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pregnant. * History of chronic or recurrent severe inflammatory eye disease. * Ocular trauma within the past six months in either eye. * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Mean intraocular pressure (IOP) change at 3 months from baseline

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.